Literature DB >> 7648975

Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse.

E Louis1, J Belaiche, C Van Kemseke, N Schaaf, P Mahieu, J Y Mary.   

Abstract

In Crohn's disease, the activity of the disease is difficult to evaluate and the evolution of the disease is difficult to predict. The soluble interleukin-2 receptor serum level has been reported to correlate with clinical activity of the disease and with mucosal immune activation. We compared serum soluble interleukin-2 receptor to classical inflammatory markers and other immune parameters in the assessment of clinical disease activity and prediction of relapse in patients with Crohn's disease. Soluble interleukin-2 receptor serum levels correlated well with the Crohn's disease activity index, and multivariate analysis showed that this correlation was independent of the other inflammatory and immune markers. The correlation was not greater, However, than that between some inflammatory markers, such as ESR, and Crohn's disease activity index. Longitudinal follow-up showed that a high soluble interleukin-2 receptor serum level was highly predictive of relapse. Multivariate analysis showed that the soluble interleukin-2 recepteur serum level was complementary to other inflammatory and clinical markers in the prediction of relapse of disease. We conclude that soluble interleukin-2 receptor is of use in monitoring Crohn's disease, particularly in prediction of relapse.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7648975     DOI: 10.1007/bf02212697

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  14 in total

1.  Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity.

Authors:  J E Crabtree; L D Juby; R V Heatley; A J Lobo; D W Bullimore; A T Axon
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

2.  Plasma and tissue interleukin-2 receptor levels in inflammatory bowel disease.

Authors:  Y R Mahida; A Gallagher; L Kurlak; C J Hawkey
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

3.  Soluble interleukin 2 and CD8 and CD4 receptors in inflammatory bowel disease.

Authors:  T Matsuura; G A West; J S Klein; L Ferraris; C Fiocchi
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

4.  A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease.

Authors:  C Brignola; M Campieri; G Bazzocchi; P Farruggia; A Tragnone; G A Lanfranchi
Journal:  Gastroenterology       Date:  1986-12       Impact factor: 22.682

Review 5.  The immunologic basis of inflammatory bowel disease.

Authors:  W Strober; S P James
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

6.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

Authors:  R Modigliani; J Y Mary; J F Simon; A Cortot; J C Soule; J P Gendre; E Rene
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

7.  Acute phase proteins in chronic inflammatory bowel disease in childhood.

Authors:  C A Campbell; J A Walker-Smith; P Hindocha; M Adinolfi
Journal:  J Pediatr Gastroenterol Nutr       Date:  1982       Impact factor: 2.839

8.  T-cell activation in Crohn's disease. Increased levels of soluble interleukin-2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cells.

Authors:  C Mueller; P Knoflach; C C Zielinski
Journal:  Gastroenterology       Date:  1990-03       Impact factor: 22.682

9.  C-reactive protein as a predictor of relapse in asymptomatic patients with Crohn's disease.

Authors:  C André; L Descos; J Vignal; J Gillon
Journal:  Scott Med J       Date:  1983-01       Impact factor: 0.729

10.  Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin.

Authors:  J Brynskov; N Tvede
Journal:  Gut       Date:  1990-07       Impact factor: 23.059

View more
  5 in total

1.  Gut mucosal secretion of interleukin 1beta and interleukin-8 predicts relapse in clinically inactive Crohn's disease.

Authors:  I D Arnott; H E Drummond; S Ghosh
Journal:  Dig Dis Sci       Date:  2001-02       Impact factor: 3.199

Review 2.  Are we giving biologics too much time? When should we stop treatment?

Authors:  Edouard Louis; J Belaiche; C Reenaers
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

Review 3.  Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.

Authors:  Jason Orlando Dimitri Musci; Jack Stephen Cornish; Jan Däbritz
Journal:  J Gastroenterol       Date:  2016-03-14       Impact factor: 7.527

4.  99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease.

Authors:  Alessio Annovazzi; Livia Biancone; Renato Caviglia; Marco Chianelli; Gabriela Capriotti; Stephen J Mather; Renzo Caprilli; Francesco Pallone; Francesco Scopinaro; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-09       Impact factor: 9.236

Review 5.  How to predict clinical relapse in inflammatory bowel disease patients.

Authors:  Elisa Liverani; Eleonora Scaioli; Richard John Digby; Matteo Bellanova; Andrea Belluzzi
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.